Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
Open on Zacks
Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2026, Gilead Sciences (GILD) reported revenue of $8.3 billion, up 6.8% over the same period last year. EPS came in at $2.55, compared to $2.47 in the year-ago quarter.

The reported revenue represents a surprise of +6.21% over the Zacks Consensus Estimate of $7.81 billion. With the consensus EPS estimate being $2.17, the EPS surprise was +17.51%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- Total Liver Disease- U.S.: $524 million versus the three-analyst average estimate of $450.89 million. The reported number represents a year-over-year change of +26.6%. Product Sales- Total HIV- U.S.: $5.26 billion versus $4.8 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +22.4% change. Product Sales- Other- Other- U.S.: $36 million compared to the $22.64 million average estimate based on three analysts. The reported number represents a change of +5.9% year over year. Total product sales- U.S.: $6.36 billion versus the three-analyst average estimate of $5.74 billion. The reported number represents a year-over-year change of +20.6%. Product Sales- HIV- Odefsey- Total: $286 million compared to the $202.57 million average estimate based on three analysts. The reported number represents a change of +3.3% year over year. Total product sales- Total: $8.29 billion versus the three-analyst average estimate of $7.75 billion. The reported number represents a year-over-year change of +12.9%. Revenues- Royalty contract and other revenues: $11 million compared to the $62.02 million average estimate based on three analysts. The reported number represents a change of -97.4% year over year. Product Sales- Liver Disease- Vemlidy- Total: $333 million compared to the $252.48 million average estimate based on three analysts. The reported number represents a change of +18.9% year over year. Product Sales- Oncology- Cell Therapy- Yescarta- Total: $294 million versus the three-analyst average estimate of $305.72 million. The reported number represents a year-over-year change of -15.8%. Product Sales- HIV- Biktarvy- Total: $4.06 billion compared to the $3.95 billion average estimate based on three analysts. The reported number represents a change of +10.1% year over year. Product Sales- HIV- Symtuza-Revenue share- Total: $132 million compared to the $125.65 million average estimate based on three analysts. The reported number represents a change of +6.5% year over year. Product Sales- Veklury- Total: $86 million versus $77.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -69% change.

View all Key Company Metrics for Gilead here>>>

Shares of Gilead have returned +6.8% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research